REFERENCES

1. Andrésdóttir MB, van Hamersvelt HW, van Helden MJ, van de Bosch WJ, Valk IM, Huysmans FT. Ankle Edema Formation during Treatment with the Calcium Channel Blockers Lacidipine and Amlodipine: A Single-centre Study. J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S25-30.
2. Bhandari P, et al. Chirality - Today and Tomorrow's way of treatment. Available at http://www.chiralemcure.com/downloads.asp, accessed on 5th January 2012
3. Cho S, Atwood JE. Peripheral edema. Am J Med. 2002;113: 580-586.
4. Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm. 1994 Jan;51(1):59-68.
5. Cross BW, Kirby MG, Miller S, Shah S, Sheldon DM, Sweeney MT. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. The British Journal of Clinical Practice 1993;47(5):237-40.
6. Damasceno A, Santos A, Postana M, et al. Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects. J Cardiovasc Pharmacol. 1999;34:346-353.
7. Domenic A. Sica, MD. Calcium Channel Blocker-Related Peripheral Edema: Can It Be Resolved? Available at http://www.medscape.com/viewarticle/460070_3, accessed on 25th May 2012
8. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res Clin Exp. 2000;61:850-862.
9. Gustafsson D, Lanne T, Bjerkhoel P, et al. Microvascular mechanisms and oedema formation of felodipine in man. J Hypertens. 1989;7(suppl 4):S161-S167.
10. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol. 1987; 10(suppl 1):S121-S131.
11. Kim SA, Park S, Chung N, Lim DS, Yang JY, Oh BH, et al. Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized,

double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial. Clin Ther. 2008 May;30(5):845-57.

12. Kloner RA, Weinberger M, Pool JL, et al. Comparative effects of candesartan cilexitil and amlodipine in patients with mild systemic hypertension. Am J Cardiol. 2001;87:727-31.
13. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15:932-940.
14. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients with lercanidipine or amlodipine. J Hypertens. 2003;21:1003-1010.
15. Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P; Val-Syst study. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003 Nov;25(11):2765-80.
16. Messerli FH, Grossman E. Pedal edema--not all dihydropyridine calcium antagonists are created equal. Am J Hypertens. 2002 Nov;15(11):1019-20.
17. Messerli FH. Vasodilatory edema: A common side effect of antihypertensive therapy. Current Cardiology Reports 2002;4(6):479-82.
18. Muntwyler J, Follath F. Calcium channel blockers in treatment of hypertension. Prog Cardiovasc Dis. 2001 Nov-Dec;44(3):207-16.
19. Oh GC, Lee HY, Kang HJ, Zo JH, Choi DJ, Oh BH. Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical trial. Clin Ther. 2012 Sep;34(9):1940-7.
20. Osterloh I. The safety of amlodipine. American Heart Journal. 1989;118(5):1114–20.
21. Pathak L, Hiremath, Kerkar PG, Manade VG. Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. J Assoc Physicians India. 2004 Mar;52:197-202.
22. Paudel R, Palaian S, Kishore PV, Shankar PR, Mishra P. Peripheral edema due to S-amlodipine - a report of three cases. Journal of Clinical and Diagnostic Research. 2007;1(6):533-6.

23. Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35(2):621-5.
24. Schoeller DA, Alon A, Manekas D, Mixson LA, Lasseter KC, Noonan GP, et al. Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study. Clin Ther. 2012 Mar;34(3):580-92.
25. Sierkova VK, Kuz'minova NV, Alshantti IS. Comparative estimation of efficiency and safety of racemic amlodipine and its S-enantiomer in hypertensive patients. Lik Sprava. 2009 Apr-Jun;(3-4):39-44.
26. Stanek EJ, Nelson CE, DeNofrio D. Amlodipine overdose. Ann Pharmacother July/August 1997;31(7/8):853-56.
27. Thacker HP. S-amlodipine--the 2007 clinical review. J Indian Med Assoc. 2007 Apr;105(4):180-2, 184, 186 passim.
28. Tsutamoto T, Tsutsui T, Maeda K, et al. Effects of long-acting calcium channel antagonists on neurohumoral factors: comparison of nifedipine coat-core with amlodipine. J Cardiovasc Pharmacol. 2003;41(suppl 1):S77-S81.
29. Zanchetti A, Omboni S, La Commare P, et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001;38:642-650.